Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer

Background To examine influences on the receptor status of a local cohort of patients with recurrent breast cancer after primary diagnosis of hormone receptor positive breast cancer. Methods We retrospectively analyzed 2078 female patients with primary hormone receptor positive breast cancer treated...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gynecology and obstetrics 2019-02, Vol.299 (2), p.533-541
Main Authors: Stueber, Tanja Nadine, Weiss, Claire Rachel, Woeckel, Achim, Haeusler, Sebastian
Format: Article
Language:English
Subjects:
Biology
Biopsy
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant - methods
Endocrine therapy
Endocrinology
Female
Gynecologic Oncology
Gynecology
Human Genetics
Humans
Lymphatic system
Mastectomy
Medical records
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Obstetrics
Obstetrics/Perinatology/Midwifery
Prognosis
Retrospective Studies
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background To examine influences on the receptor status of a local cohort of patients with recurrent breast cancer after primary diagnosis of hormone receptor positive breast cancer. Methods We retrospectively analyzed 2078 female patients with primary hormone receptor positive breast cancer treated at the university hospital of Wuerzburg between 2000 and 2013. Main focus was on discordance in receptor status in recurrent disease. Results 196 patients with the primary diagnosis of hormone receptor positive breast cancer developed recurrent disease. 29.1% of patients revealed discordance in estrogen receptor (ER), progesterone receptor (PgR) or HER2 receptor (ER +  to  − : 33.3%; PgR +  to  − : 59.6%; HER2 +  to  − : 8.8%; HER2 −  to  + : 17.5%). Aggressive tumor biology such as low grading or involvement of axillary lymph nodes showed increased risk of receptor conversion in relapse. Premenopausal patients with adjuvant application of tamoxifen and the application of chemotherapy had a significantly lower risk for the development of ER negative recurrent disease. Receptor changes to ER and PgR negativity in recurrent disease showed a trend to worse overall survival (OS). Conclusions Histological analysis of recurrent disease is indispensable, since one-third of patients with hormone receptor positive breast cancer develop change in the receptor status.
ISSN:0932-0067
1432-0711
DOI:10.1007/s00404-018-4954-7